



Welcome to Almac Group





Alan Armstrong

Chairman & CEO

Welcome to The Almac Group

The Almac Group is a global leader in providing a range of expert services and support across the drug development lifecycle.

We are trusted experts in R&D, diagnostic services, API manufacture, formulation development, clinical trial supply services and technologies through to commercial-scale manufacture and distribution.

Recognised as an industry leader in client service, we provide understanding, experience and knowledge to our clients as we work together to advance human health.

We are trusted by the leading global biopharma companies to provide crucial services across their drug development projects. In the last five years alone, we have played a contributory role in approximately 50% of all FDA approved New Molecular Entities (NMEs) and we are currently supporting 30% of EU approved / pre-registered Genetherapy products.

A privately owned organisation, Almac has grown organically over the past five decades, employing over 7,000 highly skilled employees across 18 facilities in Europe, North America, and Asia.



Enoss

ALMAC
Diagnostic

Our areas of specialism

We play a vital role in the development of new medicines and treatments. Our innovative services range from R&D, biomarker discovery development and commercialisation, through to product sales.

Our areas of specialism are:

- Drug discovery
- Diagnostic services
- API, chemical development & analytical services
- Pharmaceutical development
- Clinical services
- Clinical technologies
- Commercial services
- Product sales, marketing & launch services

Our unique combination of inspirational people, exceptional innovation and outstanding quality, enables us to work with you in the most appropriate manner for your situation: either on a single standalone project or on a long-term basis as your strategic partner.



Drug discovery

A research driven drug discovery business dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need.

The Almac Discovery business model focuses on the development of First-in-Class pre-clinical stage assets which are then licenced to pharmaceutical partners for further development.

We also seek to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest.

Key research themes include deubiquitinase enzymes and protein drug conjugates.



Diagnostic services

Diagnostic Services supports global pharma and biotech companies with their biomarker strategies from discovery through to companion diagnostic partnerships. We have CLIA and CAP accredited laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies.

We offer a unique business model to support clients, providing complete flexibility to develop and validate custom assays from a range of platform and chemistry options, across many different sample types and disease indications. We also support all CDx commercial models from single site PMA to IVD Kit.

Our supporting services include Data Sciences, Regulatory Expertise, Project Management and Clinical Support.

The core services we offer fall into three main categories:

- Genomic Services
- Clinical Trial Assays
- Companion Diagnostics



API, chemical development & analytical services

Delivering services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API) for small molecules (including highly potent) and peptides.

Almac Sciences have a proven track record of saving time and costs through the integration of our services and application of innovative biocatalysis and technology solutions. Supported by our radiolabelling, physical sciences and global analytical services teams, think Almac for drug development outsourcing solutions.

Offering a full suite of analytical testing services across three FDA approved laboratories, encompassing method development, validation, transfer and stability studies on small molecule, biologics, active ingredients and finished products, (including controlled substances), Almac's team of >250 analysts have the capacity and capability to deliver your project.



Pharmaceutical development

Addressing the increasing pressure on pharmaceutical companies to bring clinical candidates through their pipeline faster and with greater efficiency, Almac Pharma Services provides expert pharmaceutical drug product development solutions.

Our scientists can develop clinical candidates into optimum formulations, provide analytical testing, and manufacture solid oral dose products for all stages of clinical trials. From developing a fit-for-purpose formulation for First-in-Human trials, to scaling up for late phase trials.



Clinical services

Vast experience in providing an expanding array of best-in-class solutions to the global pharmaceutical and biotech industries.

Guided by our extensive clinical supply experience and expertise, Almac Clinical Services is recognised as an innovative, global solutions provider within the specialised and complex market of clinical trial supply.

Our integrated and adaptable solutions, offer the most flexible approach to support the delivery of global clinical trials from protocol right through to patient delivery.

Our core purpose is to be the partner of choice, to deliver the next generation of health care solutions effectively and to focus on winning for you and your patients.



Clinical technologies

Helping the biopharmaceutical industry bring new therapies to those in need by empowering trial sponsors to proactively manage sites, patients and clinical supplies through our industry-leading Interactive Response Technology (IRT) and expert consultancy.

The solutions offered by Almac Clinical Technologies facilitate more than simplifying patient and trial material management - they engineer quality into the clinical trial process. Our technology provides sponsors and CROs with the visibility and control needed to make data-driven decisions by leveraging advanced supply management functionality coupled with real-time site and patient data in a closed-loop environment.

Our expertise, energy and commitment have earned us a reputation as a trusted ally in the drug development process.



Commercial services

Providing a wide range of tailor-made product launch solutions, commercial manufacturing, primary and secondary packaging, and global distribution.

Scaling up from our development services to full scale commercial drug product manufacture or transferring existing commercial products, we can meet commercial solid oral dose drug product manufacturing requirements.

Bespoke specialised packaging of complex kit assembly and ultra-low temperature storage and packaging processes specifically for unique and niche products. With an emphasis on client partnership and meeting patient needs.

We offer flexible, quality-led commercial solutions, and customisable GMP floor space. Onsite complementary support services of analytical testing, storage packaging design & artwork, serialisation and QP services provide a comprehensive strategic solution.



Product sales, marketing & launch services

Under the brand name Galen, we help our partner companies grow and expand into new markets through sales, marketing and launch excellence. In addition to our established market access we also offer expertise in medical affairs, pharmacovigilance and regulatory affairs.

We are positioned to distribute products worldwide, with commercial operations based in the UK & Ireland, the Nordics, Germany, and the USA as well as global partners on every continent.

We pride ourselves on developing genuine relationships with our partners, crafting commercial strategy together and maintaining an open channel of communication as we manage their product to success.

Galen's purpose is to be of Extraordinary Service to our patients, suppliers and health care professionals and we are committed to going above and beyond to meet their needs, so that together we can benefit the health of all generations.



Corporate social responsibility

At Almac we strive to take care of our people, protect our planet and make a positive contribution to our communities.

As part of our commitment to sustainability we will:

- Reduce our carbon emissions and energy use, and meet our committed net zero target
- Support, develop and reward our people to create a workplace where employees from all backgrounds feel welcome and have opportunities to reach their full potential
- Contribute to the overall advancement of human health through our work with our partners and via the philanthropy of the McClay Foundation
- Support and give back to our communities
- Operate to the highest ethical standards

For more information on our CSR approach please visit:

almacgroup.com/csr



Our Global Locations

UK & Europe

Global HQ - Craigavon, Northern Ireland
Belfast, Northern Ireland (2)
Derry/Londonderry, Northern Ireland
Elvingston, Scotland
Charnwood, England
Manchester, England
Dundalk, Ireland
Athlone, Ireland (2)
Birkerød, Denmark
Sprockhövel, Germany

USA

US HQ - Souderton, PA
Audubon, PA
Lansdale, PA
Durham, NC

Asia Pacific

Asia HQ - Singapore
Tokyo, Japan



The McClay Foundation

The McClay Foundation, which wholly owns The Almac Group, was founded by Sir Allen McClay and exists to make meaningful improvement and advancement in human health.

The McClay Foundation's objectives are:

1. To support and encourage research and innovation.
2. To advance the use of diagnostic tools and drugs in the prevention, control and cure of diseases.
3. To ensure latest advances in healthcare are available to all, including developing countries.
4. To generate and promote employment opportunities.
5. To support and promote such educational purposes as the trustees shall select, provided that such

The McClay Foundation's four strategic focus areas are:

- Research and Development of New Medicines
- Oncology Research - Targets and Biomarkers
- Research led care for those in end of life or life limited circumstances
- Promoting health and wellbeing in disenfranchised communities and geographical locations

With 18 locations and a further 60 depots around the world,
we are where our clients and patients need us to be.

7,000+

Employees globally

50%+

Contributed to over
half of approved
NMEs in the last 6
years

50+

Years of experience

25

Work with top
25 BioPharma
companies

18

Almac facilities

almacgroup.com

GET IN TOUCH

Global HQ

+44 28 3833 2200

US HQ

+1 215 660 8500

Asia HQ

+65 6309 0720

EU HQ

+353 42 932 0718

Durham, NC, USA

+1 (919) 479 8850

Japan

+81 367 218720